Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer
Phase 1
Terminated
- Conditions
- Prostate Cancer
- Registration Number
- NCT00096304
- Lead Sponsor
- Medical University of South Carolina
- Brief Summary
RATIONALE: Drugs used in chemotherapy, such as epirubicin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of epirubicin when given with docetaxel in treating patients with metastatic prostate cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Male
- Target Recruitment
- 36
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hollings Cancer Center at Medical University of South Carolina
🇺🇸Charleston, South Carolina, United States